SCHEMBL277403

SCHEMBL277403

CCCC(C)C(CC)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 1/20 0.54
AKR1A1 P14550 1/20 0.54
CHRM3 P20309 1/20 0.54
HTR2A P28223 1/20 0.54
HTR2C P28335 1/20 0.54
ADRA1A P35348 1/20 0.54
HRH1 P35367 1/20 0.54
DRD3 P35462 1/20 0.54
SLC6A3 Q01959 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC2 Q92769 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
CA2 P00918 1/20 0.41
MAPK1 P28482 1/20 0.41
CYP3A4 P08684 2/20 0.41
TSHR P16473 2/20 0.41
NFKB1 P19838 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
METAP1 P53582 1/20 0.39
SLC1A3 P43003 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11805982 0.88 CHRM1 (0.50) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL4470713 0.86 CA2 (0.54) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL6431145 0.86 CA2 (0.54) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL29013997 0.85 CHRM1 (0.41) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL28504059 0.85 GPR84 (0.50) CHRM1AKR1A1CHRM3HTR2AHTR2C
SCHEMBL8028598 0.83 GPR84 (0.53) CA2MAPK1GRIK1GRIK2ACE2
SCHEMBL6744021 0.83 GPR84 (0.53) CA2MAPK1GRIK1GRIK2ACE2
SCHEMBL1116066 0.83 GPR84 (0.53) CA2MAPK1GRIK1GRIK2ACE2
SCHEMBL29126788 0.83 GPR84 (0.53) CA2MAPK1GRIK1GRIK2ACE2
SCHEMBL13040584 0.82 ACE (0.46) CHRM1AKR1A1CHRM3HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107903985-A A kind of synthesizing ester tractive transformer fluid composition and preparation method thereof 中国科学院长春应用化学研究所 2018-04-13 CN claimed
CN-116659004-B Air conditioner DAIKIN INDUSTRIES, LTD. (JP) 2026-05-26 CN disclosed
EP-4711434-A1 REFRIGERANT CYCLE APPARATUS Daikin Industries, Ltd. (JP) 2026-03-18 EP disclosed
EP-4234293-B1 REFRIGERATION CYCLE DEVICE FOR VEHICLE DAIKIN IND LTD (JP) 2025-12-24 EP disclosed
US-12441922-B2 Refrigerant-containing composition, use of same, refrigerator having same, operation method for said refrigerator, and refrigeration cycle device equipped with same DAIKIN INDUSTRIES, LTD. (JP) 2025-10-14 US disclosed
EP-4245830-B1 LUBRICANT BASE OIL KAO CORP (JP) 2025-09-10 EP disclosed
US-20250115796-A1 REFRIGERATION CYCLE APPARATUS DAIKIN INDUSTRIES, LTD. (JP) 2025-04-10 US disclosed
CN-116731775-B Refrigerating cycle device, refrigerating machine oil, and refrigerant leakage preventing agent 大金工业株式会社 2025-02-18 CN disclosed
EP-4083174-B1 REFRIGERATION CYCLE DEVICE, REFRIGERATION MACHINE OIL AND REFRIGERANT LEAKAGE PREVENTION AGENT DAIKIN IND LTD (JP) 2025-01-22 EP disclosed
EP-3825383-B1 REFRIGERATION CYCLE DEVICE FOR VEHICLE DAIKIN IND LTD (JP) 2024-11-06 EP disclosed
EP-1947101-A1 HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2008-07-23 EP disclosed
US-7351841-B2 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2008-04-01 US disclosed
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2008-01-31 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed
EP-1819692-A1 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS Nissan Chemical Industries, Ltd. (JP) 2007-08-22 EP disclosed
CN-1798739-A 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators NISSAN CHEMICAL IND LTD (JP) 2006-07-05 CN disclosed
WO-2006062240-A1 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2006-06-15 WO disclosed
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NISSAN CHEMICAL INDUSTRIES LIMITED (JP) 2006-05-04 US disclosed
EP-1636192-A1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS Nissan Chemical Industries, Ltd. (JP) 2006-03-22 EP disclosed
WO-2004108683-A1 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094694-A1 Heterocyclic compounds and thrombopoietin receptor activators NR2C2, ROR1, NR0B2 CHRM1 1015/4885AKR1A1 1222/4885CHRM3 1569/4885
US-20080027068-A1 HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS NR2C2, ROR1, NR0B2 CHRM1 872/4885AKR1A1 1282/4885CHRM3 1420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.